Previous Close | 1,519.00 |
Open | 1,527.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 1,501.50 - 1,537.00 |
52 Week Range | 922.45 - 1,638.85 |
Volume | |
Avg. Volume | 2,738,705 |
Market Cap | 3.616T |
Beta (5Y Monthly) | 0.53 |
PE Ratio (TTM) | 40.55 |
EPS (TTM) | 37.17 |
Earnings Date | May 24, 2024 - May 28, 2024 |
Forward Dividend & Yield | 12.50 (0.83%) |
Ex-Dividend Date | Feb 09, 2024 |
1y Target Est | 829.22 |
In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global Pharmaceutical Drugs Market According to a report by The Business Research […]
In this article, we will look into the top 20 most valuable Indian companies. If you want to skip our detailed analysis, you can go directly to the Top 5 Most Valuable Indian Companies. An Outlook of the Indian Economy According to Deloitte’s Indian Economic Outlook 2023, The Indian economy is poised to emerge as […]
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming intern